Loading...

PULM PULMATRIX INC Operational Disruptions 8-K Filing

PLMT

PLM

PULMATRIX INC

(PULM)

2024 8-K

Summary

Summary

Financial Results Report

Financial Statements

Merger of Equals

Financial Statements

Financial Results

Bylaw Amendment

Annual Meeting Results

Merger Agreement

Financial Results

Annual Meeting Notice

Q2 Financial Results

Departure of Directors and ...

Agreement for Facility Tran...

Earnings Reports

Earnings Reports

Termination of Chief Medica...

Presentation Distribution

Termination of Clinical Stu...

Earnings Reports

Earnings Reports

Earnings Reports

Earnings Reports

Announcement of Phase 2b Tr...

Regulation FD Disclosure

Investor Presentation

Phase 1 Trial Completion

External Links:

Pulmatrix, Inc. issued a press release announcing the publication of a Phase 1 study on their dry powder formulation of dihydroergotamine.

AI Assistant

PULMATRIX INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.